Novozymes Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Ester Baiget

Chief executive officer

DKK 29.1m

Total compensation

CEO salary percentage	33.3%
CEO tenure	4.2yrs
CEO ownership	n/a
Management average tenure	1.7yrs
Board average tenure	3.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ester Baiget's remuneration changed compared to Novozymes's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	DKK 29m	DKK 10m	DKK 3b
Sep 30 2023	n/a	n/a	DKK 3b
Jun 30 2023	n/a	n/a	DKK 3b
Mar 31 2023	n/a	n/a	DKK 4b
Dec 31 2022	DKK 24m	DKK 10m	DKK 4b
Sep 30 2022	n/a	n/a	DKK 3b
Jun 30 2022	n/a	n/a	DKK 3b
Mar 31 2022	n/a	n/a	DKK 3b
Dec 31 2021	DKK 24m	DKK 8m	DKK 3b
Sep 30 2021	n/a	n/a	DKK 3b
Jun 30 2021	n/a	n/a	DKK 3b
Mar 31 2021	n/a	n/a	DKK 3b
Dec 31 2020	DKK 24m	DKK 7m	DKK 3b

Compensation vs Market: Ester's total compensation ($USD4.24M) is about average for companies of similar size in the MX market ($USD5.82M).

Compensation vs Earnings: Ester's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Ester Baiget (52 yo)

4.2yrs

Tenure

DKK 29,100,000

Compensation

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ester Baiget	President & CEO	4.2yrs	DKK 29.10m	no data
Rainer Lehmann	Executive VP & CFO	less than a year	DKK 6.40m	no data
Anders Lund	Chief Operating Officer	less than a year	DKK 7.70m	no data
Claus Fuglsang	Chief Scientific Officer	3.6yrs	no data	no data
Tobias Bjorklund	Head of Investor Relations	no data	no data	no data
Winnie Bugel	General Counsel of Legal	less than a year	no data	no data
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	no data	no data
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3yrs	no data	no data
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.2yrs	DKK 7.60m	no data
Amy Byrick	Executive Vice President of Human Health Biosolutions	3yrs	no data	no data
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	no data	no data
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	no data	no data

1.7yrs

Average Tenure

49.5yo

Average Age

Experienced Management: NSIS N's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jesper Brandgaard	Vice Chair of the Board	less than a year	no data	no data
Cornelis de Jong	Independent Chairman	4.2yrs	DKK 1.78m	0.0011% MX$ 4.5m
Kim Stratton	Independent Vice Chair	7.2yrs	DKK 1.29m	no data
Kasim Kutay	Director	7.2yrs	DKK 803.00k	0.00023% MX$ 965.4k
Heine Dalsgaard	Director	4.2yrs	DKK 1.07m	0.00065% MX$ 2.7m
Lise Kaae	Director	less than a year	no data	no data
Anders Knudsen	Employee Representative Director	11.2yrs	DKK 535.00k	no data
Sharon James	Independent Director	4.2yrs	DKK 1.07m	no data
Anne Breum	Employee Representative Director	3.1yrs	DKK 535.00k	0.00010% MX$ 419.7k
Preben Nielsen	Employee Representative Director	3.1yrs	DKK 803.00k	0.000090% MX$ 377.8k
Jens Obro	Employee Representative Director	3.1yrs	DKK 535.00k	0.00012% MX$ 503.7k
Morten Otto Sommer	Independent Director	2.1yrs	DKK 1.03m	0.00022% MX$ 923.4k

3.6yrs

Average Tenure

59yo

Average Age

Experienced Board: NSIS N's board of directors are considered experienced (3.6 years average tenure).

Novozymes Management

Management criteria checks 2/4

Key information

Recent management updates

Novozymes A/S Announces Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Investor sentiment improves as stock rises 18%

Less than half of directors are independent

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Less than half of directors are independent

Investor sentiment deteriorates as stock falls 17%

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Less than half of directors are independent

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Less than half of directors are independent

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Less than half of directors are independent

Upcoming dividend of kr.5.50 per share

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Revenue Guidance for 2022

Less than half of directors are independent

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS kr.3.17 (vs kr.2.89 in 1Q 2020)

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team